Technical Analysis for CLRB - Cellectar Biosciences, Inc.

Grade Last Price % Change Price Change
grade D 2.74 17.09% 0.40
CLRB closed up 17.09 percent on Monday, March 18, 2019, on 4.38 times normal volume.

Earnings due: Mar 19

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Up
See historical CLRB trend table...

Date Alert Name Type % Chg
Mar 18 New Uptrend Bullish 0.00%
Mar 18 Pocket Pivot Bullish Swing Setup 0.00%
Mar 18 Volume Surge Other 0.00%
Mar 18 Wide Range Bar Range Expansion 0.00%
Mar 18 Upper Bollinger Band Walk Strength 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 18 Above Upper BB Strength 0.00%
Mar 18 Up 3 Days in a Row Strength 0.00%
Mar 18 Upper Bollinger Band Touch Strength 0.00%
Mar 15 Pocket Pivot Bullish Swing Setup 17.09%

Older signals for CLRB ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Medicine Cancer Clinical Medicine Imaging Oncology Chemotherapy Stem Cells Radiation Antineoplastic Drugs Occupational Safety And Health Radiation Therapy Glioblastoma Targeted Therapy Solid Tumor Tomography Advanced Solid Tumors Ros1
Is CLRB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 12.9
52 Week Low 1.22
Average Volume 105,091
200-Day Moving Average 3.4451
50-Day Moving Average 1.9854
20-Day Moving Average 2.0855
10-Day Moving Average 2.161
Average True Range 0.2324
ADX 25.21
+DI 31.638
-DI 10.2365
Chandelier Exit (Long, 3 ATRs ) 2.0428
Chandelier Exit (Short, 3 ATRs ) 2.3972
Upper Bollinger Band 2.443
Lower Bollinger Band 1.728
Percent B (%b) 1.42
BandWidth 34.284344
MACD Line 0.1118
MACD Signal Line 0.0533
MACD Histogram 0.0585
Fundamentals Value
Market Cap 38.15 Million
Num Shares 13.9 Million
EPS -1.13
Price-to-Earnings (P/E) Ratio -2.42
Price-to-Sales 0.00
Price-to-Book 1.98
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.46
Resistance 3 (R3) 3.38 3.06 3.34
Resistance 2 (R2) 3.06 2.88 3.10 3.30
Resistance 1 (R1) 2.90 2.76 2.98 2.98 3.26
Pivot Point 2.58 2.58 2.62 2.62 2.58
Support 1 (S1) 2.42 2.40 2.50 2.50 2.22
Support 2 (S2) 2.10 2.28 2.14 2.18
Support 3 (S3) 1.94 2.10 2.14
Support 4 (S4) 2.02